301.694.2999

DONATE

Celebrating 30+ Years of Impact THE NEXT CHAPTER FITCI: 321 Ballenger Center Drive, Suite, 125, Frederick, Maryland 21703August 7, 2026, 3 PM – 6 PM ADMISSION FREE REGISTRATION Building Leaders, Elevating Talent, and Strengthening Communities Since 1995 FOR IMMEDIATE RELEASE – MAIA Management Group, LLC proudly announces a renewed chapter of service, leadership, and community-centered … Read more

A Coalition of Maryland Incubators join forces to expand collaboration, founder support, and statewide economic opportunity as: Network for Entrepreneurship, Xceleration & Unified Startups (NEXUS). FREDERICK, Md., May 20, 2026 /PRNewswire/ — The coalition of four Maryland incubators are collaborating on a unified approach to grow the state’s innovation economy—bringing together regional strengths, shared resources, and coordinated … Read more

Frederick, MD — Frederick Innovative Technology Center, Inc. (FITCI) announced today that its flagship innovation building, Maryland’s EDGE at 321 Ballenger Center Drive, has achieved significant energy savings through a pilot deployment of EclimAI’s AI-powered EDGE HVAC optimization device. The pilot reinforces FITCI’s commitment to creating one of the most sustainable and innovation-driven commercial environments in Maryland.  EclimAI, an … Read more

Phycin Selected for ReGen Valley Tech Hub Commercialization Award to Advance Biofabrication and Stem Cell Research Frederick, Md. — 01/05/2026 — Phycin has been selected to receive an award through the ReGen Valley Tech Hub Call for Commercialization Resources, marking a significant milestone in the company’s mission to advance next-generation biofabrication and stem cell research … Read more

Washington, D.C.—In a breakthrough that could reshape the future of cancer care, Nanocrine—a Maryland-based biotech startup—has unveiled its RT-Chip™ technology, a next-generation biosensor platform that enables real time observation of tumor activity at the cellular level. “We have overcome a major obstacle in cancer treatment:  the inability to monitor how tumor cells interact and respond … Read more

WHEN:                 Dec 4, 2025, 9:30am WHERE:              Bloomberg Briefing Room, National Press Club, Washington DC FREDERICK Md.– Researchers are unveiling a breakthrough lab technique that advances the new age of personalized cancer care.  Nanocrine says its RT-Chip™ for live cell imaging for the first time enables scientists the ability to visualize cell-to-cell signaling as it is … Read more

Nanocrine – Press Conference Announcement Preview of breakthrough research to be unveiled Dec. 6th – Nanocrine WHEN: Dec 4, 2025 at 9:30am   WHERE:   Bloomberg Room https://www.press.org/events/press-conference CONTACT: Ken Wolf: 617-388-3453, kwolf@nanocrine.com                      Kathie Callahan Brady: 301-694-2999 WASHINGTON DC — Preview of breakthrough research to be formally unveiled at the Dec. 6th CELL BIO2025 … Read more

Opus Technology LTD Joins FITCI’s Soft Landing Program Through Maryland Global Gateway Frederick Innovative Technology Center, Inc. (FITCI) welcomes Opus Technology Limited, a Bangladesh-based fintech and govtech software company, as part of the Maryland Global Gateway Soft Landing Program making their Soft Landing at FITCI in Frederick, Maryland. With over two decades of experience in global software development, Opus specializes in AI-driven fintech, … Read more

Scientist in white lab coat performs an experiment in a lab environment

FREDERICK, Md., Oct. 2, 2025 /PRNewswire/ — The Community Enrichment Laboratory for Learning Sciences (CELLS), in a strategic partnership with the Frederick Innovative Technology Center, Inc. (FITCI), today announced the establishment of the CELLS BioMakerSpace at FITCI. This new community biotechnology lab is designed to foster “bioliteracy” and provide a safe, accessible space for the public to … Read more

FREDERICK, Md., Aug. 26, 2025 /PRNewswire/ — Theradaptive, Inc., a clinical-stage biotechnology company pioneering targeted protein therapeutics for tissue regeneration, today announced that the first patient has been successfully treated in the RESTORE International Phase I/II Feasibility Study. This prospective, blinded, randomized, controlled study is designed to evaluate the safety and performance of OsteoAdapt™ DE, a next-generation regenerative product developed … Read more